HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a $15 price target, as stated by analyst Joseph Pantginis.
June 03, 2024 | 4:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Rigel Pharmaceuticals and maintained a $15 price target, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Rigel Pharmaceuticals' future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100